Program
dezecapavir
Also written as “VH4011499”, “[14C]-VH4011499 (oral)” and “VH4011499 low dose Injection”.
In GlaxoSmithKline's pipeline, HIV capsid protein inhibitor
. Its studies are mostly in HIV Infections, led by GlaxoSmithKline.
Furthest: phase 2, since Aug 23, 20238 company-led studies, 4 open or runningNext primary completion: Feb 18, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 84 open or running | phase 2since Aug 23, 2023 | May 23, 2022 | Feb 18, 2027phase 1 · NCT07934719 |
- Named in GlaxoSmithKline’s own pipeline as
VH4011499
, phase 2, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 23, 2022First study: phase 1 study in HIV InfectionsFirst studyNCT05393271 · 73 enrolled · United States
- Aug 21, 2023Phase 1 study in HIV InfectionsNCT06012136 · 85 enrolled · United States
- Aug 23, 2023Phase 2 study in HIV InfectionsNCT06039579 · 44 enrolled · United States, Argentina, Canada and more
- Apr 11, 2024Phase 1 study in HIV InfectionsNCT06368986 · 60 enrolled · United States
- Dec 4, 2024Phase 1 study in HIV InfectionsNCT06724640 · 168 planned · United States
- Sep 6, 2026Phase 2 study in HIV InfectionsNCT07816250 · 200 planned
- Nov 6, 20262 phase 1 studies in HIV InfectionsNCT07934719, NCT07939594
Ahead
- Feb 18, 2027Primary completion: phase 1 study in HIV InfectionsNCT07934719
- Mar 12, 2027Primary completion: phase 1 study in HIV InfectionsNCT07939594
- Aug 16, 2028Primary completion: phase 1 study in HIV InfectionsNCT06724640
- Jun 10, 2032Primary completion: phase 2 study in HIV InfectionsNCT07816250
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“HIV capsid protein inhibitor”the company's pipeline, read by Claude · source
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07939594HIV Infections | 1 | Not yet recruiting | Mar 12, 2027 | 75 |
| NCT07934719HIV Infections | 1 | Not yet recruiting | Feb 18, 2027 | 18 |
| NCT07816250HIV Infections | 2 | Not yet recruiting | Jun 10, 2032 | 200 |
| NCT06724640HIV Infections · United States | 1 | Recruiting | Aug 16, 2028 | 168 |
| NCT06368986HIV Infections · United States | 1 | Completed | Oct 2, 2024 | 60 |
| NCT06039579HIV Infections · United States, Argentina, Canada and more | 2 | Completed | Jun 24, 2024 | 44 |
| NCT06012136HIV Infections · United States | 1 | Completed | Jun 9, 2026 | 85 |
| NCT05393271HIV Infections · United States | 1 | Completed | Apr 24, 2023 | 73 |
How it is read
Names in the registry
- “VH4011499”, 6 entries
- “[14C]-VH4011499 (oral)”, 1 entry
- “VH4011499 low dose Injection”, 1 entry
- “VH4011499 high dose Injection”, 1 entry
- “VH4011499 Dose A”, 1 entry
Conditions, from the studies’ own filings
- HIV Infections, 8 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.